Due to the recent approval of a new later-line treatment option for metastatic colorectal cancer (mCRC) and related practice gaps in this setting, clinicians need updated guidance on the evidence-based use of later-line therapies for mCRC, including appropriate selection/sequencing and patient management strategies. This enduring accredited education will help oncologists focus on improving clinicians knowledge and competence in the later-line treatment of mCRC. As a result of this educational activity, learners should be better able to: 1. Review guideline recommendations for the later-line treatment of mCRC; 2. Discuss the clinical impact of approved later-line treatments in patients with mCRC; and 3. Outline personalized strategies to optimize outcomes for patients with mCRC who require later-line treatment
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/BPB
- Start Date: 2025-01-13 06:00:00
- End Date: 2025-01-13 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Takeda Pharmaceuticals (Any division) - Amount: 148911.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all